• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

GSK Forced to Halt Phase 3 Trial of the NSCLC Drug MAGE-A3

Article

GlaxoSmithKline has been forced to halt a Phase III trial assessing its MAGE-A3 cancer immunotherapeutic in patients with non-small cell lung cancer (NSCLC).

GlaxoSmithKline has been forced to halt a Phase III trial assessing its MAGE-A3 cancer immunotherapeutic in patients with non-small cell lung cancer (NSCLC).

High hopes for the experimental immunotherapy - designed to help patients stave off the return of the disease after treatment - came after it emerged that researchers would not be able to identify a subset of patients who may benefit from its therapy, hot on the heels of other disappointing data.

Last month it was revealed that the MAGRIT trial failed to meet its primary and secondary endpoints after the treatment failed to significantly extend disease-free survival (DFS) when compared to placebo, in either the overall MAGE-A3 (a specific tumour antigen) positive population or in MAGE-A3-positive patients who did not receive chemotherapy.

Read more here: http://bit.ly/1mKib9J

Source: PharmaTimes online

Related Videos
Will Shapiro
Mila Felder, MD, FACEP
Kiana Mehring, MBA, director of strategic partnerships, managed care at Florida Cancer Specialists & Research Institute (FCS)
Miriam J. Atkins, MD, FACP, president of the Community Oncology Alliance (COA) and physician and partner of AO Multispecialty Clinic in Augusta, Georgia.
Dr Lucy Langer
Edward Arrowsmith, MD, MPH
Dr Kathi Mooney
Tiago Biachi de Castria, MD, PhD, Moffitt Cancer Center
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.